MX2019000727A - Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b). - Google Patents
Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b).Info
- Publication number
- MX2019000727A MX2019000727A MX2019000727A MX2019000727A MX2019000727A MX 2019000727 A MX2019000727 A MX 2019000727A MX 2019000727 A MX2019000727 A MX 2019000727A MX 2019000727 A MX2019000727 A MX 2019000727A MX 2019000727 A MX2019000727 A MX 2019000727A
- Authority
- MX
- Mexico
- Prior art keywords
- hptp
- ptp
- target
- monoclonal antibodies
- humanized monoclonal
- Prior art date
Links
- 229940076850 Tyrosine phosphatase inhibitor Drugs 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364381P | 2016-07-20 | 2016-07-20 | |
| US201662377072P | 2016-08-19 | 2016-08-19 | |
| PCT/US2017/042855 WO2018017714A1 (en) | 2016-07-20 | 2017-07-19 | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000727A true MX2019000727A (es) | 2019-05-02 |
Family
ID=60988231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000727A MX2019000727A (es) | 2016-07-20 | 2017-07-19 | Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b). |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US10253094B2 (enExample) |
| EP (1) | EP3487518A4 (enExample) |
| JP (4) | JP7107914B2 (enExample) |
| KR (1) | KR20190031246A (enExample) |
| CN (1) | CN109715189B (enExample) |
| AU (2) | AU2017299581B2 (enExample) |
| BR (1) | BR112019001206A2 (enExample) |
| CA (1) | CA3030298A1 (enExample) |
| IL (1) | IL263936A (enExample) |
| MX (1) | MX2019000727A (enExample) |
| PH (1) | PH12019500145A1 (enExample) |
| SG (2) | SG11201900464TA (enExample) |
| WO (1) | WO2018017714A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007237096C1 (en) | 2006-04-07 | 2012-12-13 | EyePoint Pharmaceuticals, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| EP3505182A1 (en) | 2011-10-13 | 2019-07-03 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| HK1201196A1 (en) * | 2011-10-13 | 2015-08-28 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
| JP7237344B2 (ja) | 2016-06-15 | 2023-03-13 | アイカーン スクール オブ メディシン アット マウント サイナイ | インフルエンザウイルス血球凝集素タンパク質及びその使用 |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| EP3606555A4 (en) | 2017-04-07 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES |
| WO2019246363A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| AU2019324134A1 (en) * | 2018-08-20 | 2021-04-15 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
| US12257340B2 (en) * | 2018-12-03 | 2025-03-25 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| EP3959216A4 (en) * | 2019-04-24 | 2023-01-11 | Icahn School of Medicine at Mount Sinai | ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF |
| GB2589400A (en) | 2019-06-24 | 2021-06-02 | Aerpio Pharmaceuticals Inc | Formulations of tie-2 activators and methods of use thereof |
| AU2020379649A1 (en) * | 2019-11-06 | 2022-05-26 | Mannin Research Inc. | Inhibition of the VE-PTP phosphatase protects the kidney from ischemia-reperfusion injury |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1325932T5 (da) | 1997-04-07 | 2005-10-03 | Genentech Inc | Anti-VEGF antistoffer |
| ES2199804T3 (es) | 1999-03-26 | 2004-03-01 | Regeneron Pharmaceuticals, Inc. | Modulacion de la permeabilidad vascular por medio de activadores del receptor tie2. |
| US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| EP1046715A1 (en) | 1999-04-23 | 2000-10-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
| US20020068066A1 (en) * | 1999-08-20 | 2002-06-06 | Wenyuan Shi | Method for the treatment and prevention of dental caries |
| AU784231B2 (en) | 2000-06-23 | 2006-02-23 | Schering Aktiengesellschaft | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II) |
| CA2461896C (en) | 2001-09-28 | 2012-09-18 | Santen Pharmaceutical Co., Ltd. | Injections for eye tissues containing drug bonded to polyethylene glycol |
| US20050260132A1 (en) | 2001-10-17 | 2005-11-24 | Daniel Chin | Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta |
| WO2003047611A2 (en) | 2001-12-04 | 2003-06-12 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Ptp10d, tec and edtp involved in triglycerid-metabolism |
| US20030215899A1 (en) | 2002-02-13 | 2003-11-20 | Ceptyr, Inc. | Reversible oxidation of protein tyrosine phosphatases |
| WO2003092611A2 (en) | 2002-05-03 | 2003-11-13 | Regeneron Pharmaceuticals, Inc. | Methods of inducing formation of functional and organized lymphatic vessels |
| US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| RU2007135216A (ru) | 2005-02-23 | 2009-03-27 | Мерримак Фармасьютикалз, Инк. (Us) | Биспецифические связывающие агенты для модулирования биологической активности |
| WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| US20070134234A1 (en) | 2005-09-29 | 2007-06-14 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
| US20090123474A1 (en) | 2005-12-15 | 2009-05-14 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| EP1981520A2 (en) | 2006-01-30 | 2008-10-22 | (OSI) Eyetech, Inc. | Combination therapy for the treatment of neovascular disorders |
| US8044178B2 (en) * | 2006-03-10 | 2011-10-25 | Wyeth Llc | Anti-5T4 antibodies and uses thereof |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| AU2007237096C1 (en) * | 2006-04-07 | 2012-12-13 | EyePoint Pharmaceuticals, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| WO2009003110A2 (en) | 2007-06-26 | 2008-12-31 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| US8410251B2 (en) * | 2008-06-20 | 2013-04-02 | National University Corporation Okayama University | Antibody against calcified globule and use of the same |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CN102272148A (zh) | 2008-11-03 | 2011-12-07 | 分子组合公司 | 抑制vegf-a受体相互作用的结合蛋白 |
| CN108635350A (zh) | 2009-01-12 | 2018-10-12 | 爱尔皮奥治疗有限公司 | 治疗血管渗漏综合征的方法 |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| WO2010097800A1 (en) | 2009-02-26 | 2010-09-02 | Muhammad Abdulrazik | Synergistic combination of bioactive compounds for lowering of intraocular pressure |
| RU2542394C2 (ru) * | 2009-03-24 | 2015-02-20 | ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. | Гуманизированные антитела против light и их применение |
| CA2748765C (en) | 2009-07-06 | 2014-07-22 | Akebia Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| AU2010325969B2 (en) * | 2009-12-02 | 2016-10-20 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
| PH12013500577B1 (en) | 2010-10-07 | 2019-06-28 | Aerpio Therapeutics Inc | Compositions and methods for treating ocular edema, neovascularization and related diseases |
| WO2012109673A1 (en) | 2011-02-11 | 2012-08-16 | Psivida Us, Inc. | Methods of treating macular edema using antiedema therapeutics |
| WO2012158818A2 (en) * | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| HK1201196A1 (en) * | 2011-10-13 | 2015-08-28 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
| EP3505182A1 (en) | 2011-10-13 | 2019-07-03 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| UA120029C2 (uk) | 2012-07-13 | 2019-09-25 | Рош Глікарт Аг | Спосіб зниження в'язкості біспецифічного антитіла до vegf/ang-2 та застосування такого антитіла для лікування судинних очних захворювань |
| EP3721872B1 (en) | 2012-11-08 | 2025-01-22 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| GB2516561B (en) | 2013-03-15 | 2016-03-09 | Aerpio Therapeutics Inc | Compositions, formulations and methods for treating ocular diseases |
| WO2014203182A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Use of a vegf antagonist in treating choroidal neovascularisation |
| JP2016522250A (ja) | 2013-06-20 | 2016-07-28 | ノバルティス アーゲー | 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用 |
| US20160168240A1 (en) | 2013-07-11 | 2016-06-16 | Sergey AKSENOV | Use of vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients |
| AU2014288847A1 (en) | 2013-07-11 | 2016-01-28 | Novartis Ag | Use of a VEGF antagonist in treating retinopathy of prematurity |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| AU2014337135B2 (en) | 2013-10-18 | 2019-09-19 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody |
| AU2015204674B2 (en) | 2014-01-10 | 2020-09-03 | Anaptysbio, Inc. | Antibodies directed against interleukin-33 (IL-33) |
| WO2015109898A1 (zh) | 2014-01-24 | 2015-07-30 | 上海恒瑞医药有限公司 | VEGF与PDGFRβ双特异性融合蛋白及其用途 |
| CN106456614A (zh) | 2014-03-14 | 2017-02-22 | 爱尔皮奥治疗有限公司 | HPTP‑β抑制剂 |
| US9719135B2 (en) | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
| WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
| SG11201701016WA (en) | 2014-09-16 | 2017-03-30 | Ovascience Inc | Anti-vasa antibodies, and methods of production and use thereof |
| WO2016049183A1 (en) | 2014-09-24 | 2016-03-31 | Aerpio Therapeutics, Inc. | Ve-ptp extracellular domain antibodies delivered by a gene therapy vector |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| PH12017501792B1 (en) | 2015-04-02 | 2022-07-20 | Molecular Partners Ag | Recombinant binding proteins and their use |
| EP3341021A4 (en) | 2015-08-27 | 2019-03-13 | Celldex Therapeutics, Inc. | ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF |
| MX387804B (es) | 2015-09-23 | 2025-03-19 | Aerpio Therapeutics Inc | Metodos para tratar presion intraocular con activadores de tie-2 |
| SG10201911226QA (en) | 2015-09-23 | 2020-01-30 | Genentech Inc | Optimized variants of anti-vegf antibodies |
| US10894823B2 (en) | 2016-03-24 | 2021-01-19 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
-
2017
- 2017-07-19 WO PCT/US2017/042855 patent/WO2018017714A1/en not_active Ceased
- 2017-07-19 SG SG11201900464TA patent/SG11201900464TA/en unknown
- 2017-07-19 KR KR1020197002479A patent/KR20190031246A/ko not_active Ceased
- 2017-07-19 CN CN201780057896.9A patent/CN109715189B/zh active Active
- 2017-07-19 US US15/654,289 patent/US10253094B2/en active Active
- 2017-07-19 JP JP2019502696A patent/JP7107914B2/ja active Active
- 2017-07-19 EP EP17831790.5A patent/EP3487518A4/en active Pending
- 2017-07-19 BR BR112019001206A patent/BR112019001206A2/pt not_active Application Discontinuation
- 2017-07-19 AU AU2017299581A patent/AU2017299581B2/en active Active
- 2017-07-19 MX MX2019000727A patent/MX2019000727A/es unknown
- 2017-07-19 CA CA3030298A patent/CA3030298A1/en active Pending
- 2017-07-19 SG SG10201912556VA patent/SG10201912556VA/en unknown
-
2018
- 2018-11-05 US US16/180,854 patent/US10597452B2/en active Active
- 2018-11-05 US US16/180,850 patent/US10604569B2/en active Active
- 2018-12-24 IL IL263936A patent/IL263936A/en unknown
-
2019
- 2019-01-18 PH PH12019500145A patent/PH12019500145A1/en unknown
-
2020
- 2020-01-29 US US16/775,860 patent/US11136389B2/en active Active
- 2020-04-17 US US16/851,420 patent/US11180551B2/en active Active
- 2020-07-14 JP JP2020120521A patent/JP2020180156A/ja active Pending
-
2022
- 2022-05-02 JP JP2022075926A patent/JP2022101694A/ja active Pending
- 2022-05-27 US US17/804,396 patent/US12145986B2/en active Active
-
2024
- 2024-08-15 AU AU2024205789A patent/AU2024205789A1/en active Pending
- 2024-10-23 JP JP2024186570A patent/JP2025011323A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500145A1 (en) | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-á) | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| MX2024005976A (es) | Un anticuerpo anti-tigit, un anticuerpo anti-pvrig y un anticuerpo anti-pd-1 para usarse en el tratamiento de cancer. | |
| EP3991748A3 (en) | Anti-sortilin antibodies and methods of use thereof | |
| ZA201801852B (en) | Anti¿pd¿1 antibodies and compositions | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| ZA201905051B (en) | Anti-pd-1 antibodies for treatment of lung cancer | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| MX2021002616A (es) | Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2). | |
| SG10201901057UA (en) | Anti-pd-l1 antibodies | |
| MX382549B (es) | Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1. | |
| MX2018008995A (es) | Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer. | |
| MX2020009862A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| GEP20207166B (en) | Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use | |
| SG10201808519VA (en) | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies | |
| MY186711A (en) | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer | |
| MX2020002241A (es) | Anticuerpos anti-tm4sf y métodos de uso de los mismos. | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| EP4234013A3 (en) | Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3 | |
| AU2016348418A8 (en) | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| NZ729395A (en) | Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody | |
| NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
| MX391141B (es) | Anticuerpos anti-ceramida. | |
| PH12018502275B1 (en) | Interferon beta antibodies and uses thereof |